- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SELVITA Aktie jetzt für 0€ handeln | |||||
| 21.11. | Selvita Reports Significant Recovery in H2 2024, Sees Promising Outlook for the Future | 95 | PR Newswire | KRAKÓW, Poland, Nov. 21, 2024 /PRNewswire/ -- Selvita S.A. (WSE: SLV), one of the leading preclinical contract research organizations in Europe, has published... ► Artikel lesen | |
| 24.09. | Selvita S.A.: Selvita reports growing sales in Q2 and Q3, and projects increased profitability in H2 2024 | 359 | PR Newswire | KRAKÓW, Poland, Sept. 24, 2024 /PRNewswire/ -- Selvita S.A. (WSE: SLV), one of the leading preclinical contract research organizations in Europe, has published its financial results for Q2 2024... ► Artikel lesen |
2 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CORE ONE LABS | 0,079 | 0,00 % | XFRA LD6: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCORE ONE LABS INC.... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,923 | -0,97 % | Palatin Technologies, Inc.: Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy | Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathy
Demonstrated efficacy... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,220 | -11,20 % | COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization | Company leveraging core competencies to develop and commercialize natural-based products to improve health and wellness Streamlined efficiencies and cost cutting measures taken to refine operations... ► Artikel lesen | |
| AMYRIS | - | - | BioMaP-Consortium Contracts Amyris to Support Domestic Medicines Supply | ||
| HALOZYME THERAPEUTICS | 45,000 | -0,68 % | Evotec: COO-Abgang und Halozyme-Übernahmepläne | Dr. Craig Johnstone, COO von Evotec, verlässt das Unternehmen nach zwölf Jahren, während ein internes Team vorübergehend seine Aufgaben übernimmt. Parallel brodelt die Gerüchteküche um eine mögliche... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 2,810 | +0,32 % | AbCellera Reports Q2 2024 Business Results | VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced financial results for the second quarter of 2024. All financial information in this press release is reported... ► Artikel lesen | |
| GLOW LIFETECH | 0,035 | -4,11 % | Glow LifeTech Corp.: Glow Lifetech Announces Completion of Final Payment under Swiss Pharma Share Exchange Agreement and Debt Settlement | Toronto, Ontario--(Newsfile Corp. - December 20, 2024) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink: GLWLF) (FSE: 9DO) ("Glow" or the "Company") announces that, further to its news release dated December... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 317,30 | +0,60 % | Bio-Rad Reports Third-Quarter 2024 Financial Results | HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results... ► Artikel lesen | |
| AVID BIOSERVICES | 11,800 | 0,00 % | Avid Bioservices, Inc: Avid Bioservices Recommends Stockholders Vote FOR Value Maximizing Transaction | TUSTIN, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) ("Avid" or the "Company"), a dedicated biologics contract development and manufacturing organization ("CDMO")... ► Artikel lesen | |
| BIOLINERX | 0,204 | -2,86 % | BioLineRx Ltd.: BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value | - Executed license agreement with Ayrmid Ltd. for APHEXDA® (motixafortide) for $10 million upfront, up to $87 million in commercial milestones, and 18-23% tiered... ► Artikel lesen | |
| AADI BIOSCIENCE | 2,780 | +0,72 % | Aadi Bioscience +72%: NBC-Kursrakete startet über Nacht | Riesengeschenk kurz vor Weihnachten: Mitglieder des exklusiven Anlegerclubs No Brainer Club (NBC) und Teilnehmer eines Webinars feiern am Freitag eine sensationelle Kursrakete. Die Aktie von Aadi Bioscience... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 1,980 | +1,02 % | Minerva Neurosciences, Inc: Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates | BURLINGTON, Mass., Nov. 05, 2024(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business... ► Artikel lesen | |
| APPLIED THERAPEUTICS | 0,813 | -2,93 % | Applied Therapeutics Appoints John H. Johnson as Executive Chairman | Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc.... ► Artikel lesen | |
| GEOVAX LABS | 2,685 | 0,00 % | Nitches, inc: Nitches Inc. Updates Shareholders on Amazon Integration, GovX Integration, and 2025 Growth Strategy for InTheZone Labs | LAS VEGAS, NV / ACCESSWIRE / December 18, 2024 / Nitches Inc. (OTC PINK:NICH) is pleased to share key updates regarding the recent strides made with its InTheZone Labs brand, highlighting successful... ► Artikel lesen | |
| OVID THERAPEUTICS | 0,920 | -2,65 % | Ovid Therapeutics Aktie: Trends im Geschäftsfeld | Die Ovid Therapeutics Aktie verzeichnete am 29. November 2024 einen positiven Handelstag mit einem Kursanstieg von 2,70 Prozent auf 1,14 USD. Diese Entwicklung kommt nach einer schwierigen Phase, in... ► Artikel lesen |
SELVITA SA gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 11,420 Euro und damit -2,06 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SELVITA SA finden Sie auf Wallstreet Online.
